Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | CDC7 | O00311 | 6/20 | 0.63 |
| ▸ | DBF4 | Q9UBU7 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289979 | 0.90 | TRPM8 (0.65) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL8867589 | 0.89 | TRPM8 (1.00) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL12875919 | 0.87 | CDC7 (0.66) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL28297244 | 0.87 | CDC7 (0.65) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL299051 | 0.86 | CDC7 (0.64) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL2881560 | 0.85 | CDC7 (0.63) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL2885708 | 0.84 | TRPM8 (0.78) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL1316281 | 0.84 | CDC7 (0.77) | TRPM8CDC7DBF4MAPTKDM4E | |
| SCHEMBL3619382 | 0.84 | CDC7 (0.62) | TRPM8KMT2ACDC7DBF4MAPT | |
| SCHEMBL8867138 | 0.84 | CDC7 (0.62) | TRPM8KMT2ACDC7DBF4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| US-20220009918-A1 | Chemical Compounds | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-01-13 | — | — | US | disclosed |
| EP-3877384-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-09-15 | — | — | EP | disclosed |
| CN-112969698-A | Chemical compound | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-06-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009918-A1 | Chemical Compounds | HPGDS, PTGS1, PTGER1 | TRPM8 3071/4885KMT2A 3678/4885CDC7 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.